Pharmacokinetics, tolerability, and clinical effectiveness of perampanel in combination therapy for epilepsy with epilepsy
The novel antiepileptic drug (AED) perampanel is used in monotherapy and as an adjunctive treatment for focal, focal to bilateral, and generalized tonic-clonic seizures in patients with epilepsy. Perampanel has a high protein-binding ratio (> 95 %) and long half-life ( ∼105 h) and is mainly metabolized by cytochrome P450 (CYP) 3A4 [1]. Thus, it is highly susceptible to interactions with CYP-inducing AEDs (inducers), such as phenytoin (PHT), carbamazepine (CBZ), and phenobarbital (PB). In contrast, stiripentol is a strong inhibitor of CYP3A4, which can elevate perampanel concentration.
Source: Seizure: European Journal of Epilepsy - Category: Neurology Authors: Yoshiaki Yamamoto, Yuka Shiratani, Shoko Asai, Naotaka Usui, Takuji Nishida, Katsumi Imai, Yoshiyuki Kagawa, Yukitoshi Takahashi Source Type: research